The reproducibility “crisis”- Reaction to replication crisis should not stifle innovation

EMBO Reports
01 September 2017; volume 18, issue 9
http://embor.embopress.org/content/18/9?current-issue=y

Science & Society
The reproducibility “crisis”- Reaction to replication crisis should not stifle innovation
Philip Hunter
[Initial text]
The debate over a reproducibility crisis has been simmering for years now, amplified by growing concerns over a number of reproducibility studies that have failed to replicate previous positive results. Additional evidence from larger meta‐analysis of past papers also points to a lack of reproducibility in biomedical research with potentially dire consequences for drug development and investment into research. One of the largest meta‐analyses concluded that low levels of reproducibility, at best around 50% of all preclinical biomedical research, were delaying lifesaving therapies, increasing pressure on research budgets and raising costs of drug development [1]. The paper claimed that about US$28 billion a year was spent largely fruitlessly on preclinical research in the USA alone…